Cholinergic Receptor, Nicotinic, Alpha 1 Recombinant Protein | CHRNa1 recombinant protein

Recombinant Cholinergic Receptor, Nicotinic, Alpha 1 (CHRNa1)

Cat. Num. AAA2033520

• Gene Names: CHRNA1; ACHRA; ACHRD; CHRNA; CMS1A; CMS1B; CMS2A; FCCMS; SCCMS
• Applications: SDS-Page, Western Blot, ELISA, Immunoprecipitation
• Purity: >90%
• Synonyms: Cholinergic Receptor; Nicotinic; Alpha 1; Recombinant Cholinergic Receptor; Alpha 1 (CHRNa1); CHR-NA1; N-AChRA1; NAChRA1; ACHRA; ACHRD; CMS2A; FCCMS; SCCMS; Acetylcholine receptor subunit alpha; N-AChR-A1; Neuronal Acetylcholine Receptor Alpha 1; Muscle; CHRNa1 recombinant protein

• Host: E Coli
• Purity/Purification: >90%
• Form/Format: Supplied as lyophilized form in 20mM Tris, 500mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% sarcosyl, 5% trehalose, and preservative.
• Sequence: PLYFI VNVIIPCLLF SFLTGLVFYL PTDSGEKMTL SISVLLSLTVFLLVIVELIP STSSAVPLIG KYMLFTMVFV IASIIITVIV I
• Sequence Length: 457

• Applicable Applications for CHRNa1 recombinant protein: SDS-PAGE, Western (WB), ELISA (EIA), Immunoprecipitation (IP).
• Predicted Molecular Mass: 13.1kDa
• Usage: Reconstitute in sterile PBS, pH7.2-pH7.4.
• Endotoxin Level: <1.0EU per 1 ug (determined by the LAL method)
• Expression System: Prokaryotic expression
• Fragment: Pro256~Ile341
• Organism Species: Human
• Tag: two N-terminal Tags, His-tag and T7-tag
• Preparation and Storage: Avoid repeated freeze/thaw cycles. Store at 2-8 degree C for one month. Aliquot and store at -80 degree C for 12 months.; Stability Test: The thermal stability is described by the loss rate of the target protein. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37 degree C for 48h, and no obvious degradation and precipitation were observed. (Referring from China Biological Products Standard, which was calculated by the Arrhenius equation.) The loss of this protein is lessthan 5% within the expiration date under appropriate storage condition.

SDS-Page

NCBI and Uniprot Product Information

• NCBI GI #: 119631533
• NCBI GeneID: 1134
• Molecular Weight: 51,839 Da
• NCBI Official Full Name: cholinergic receptor, nicotinic, alpha 1 (muscle), isoform CRA_a
• NCBI Official Synonym Full Names: cholinergic receptor nicotinic alpha 1 subunit
• NCBI Official Symbol: CHRNA1
• NCBI Official Synonym Symbols: ACHRA; ACHRD; CHRNA; CMS1A; CMS1B; CMS2A; FCCMS; SCCMS
• NCBI Protein Information: acetylcholine receptor subunit alpha
• UniProt Protein Name: Acetylcholine receptor subunit alpha
• Protein Family: Acetylcholine receptor
• UniProt Gene Name: CHRNA1
• UniProt Synonym Gene Names: ACHRA; CHNRA
• UniProt Entry Name: ACHA_HUMAN

NCBI Description

The muscle acetylcholine receptor consiststs of 5 subunits of 4 different types: 2 alpha subunits and 1 each of the beta, gamma, and delta subunits. This gene encodes an alpha subunit that plays a role in acetlycholine binding/channel gating. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Nov 2012]

Uniprot Description

nAChRA1: After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. Defects in CHRNA1 are a cause of multiple pterygium syndrome lethal type (MUPSL). Multiple pterygia are found infrequently in children with arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal multiple pterygium syndrome there is intrauterine growth retardation, multiple pterygia, and flexion contractures causing severe arthrogryposis and fetal akinesia. Subcutaneous edema can be severe, causing fetal hydrops with cystic hygroma and lung hypoplasia. Oligohydramnios and facial anomalies are frequent. The alpha subunit is the main focus for antibody binding in myasthenia gravis. Myasthenia gravis is characterized by sporadic muscular fatigability and weakness, occurring chiefly in muscles innervated by cranial nerves, and characteristically improved by cholinesterase-inhibiting drugs. Defects in CHRNA1 are a cause of congenital myasthenic syndrome slow-channel type (SCCMS). SCCMS is the most common congenital myasthenic syndrome. Congenital myasthenic syndromes are characterized by muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. SCCMS is caused by kinetic abnormalities of the AChR, resulting in prolonged endplate currents and prolonged AChR channel opening episodes. Defects in CHRNA1 are a cause of congenital myasthenic syndrome fast-channel type (FCCMS). FCCMS is a congenital myasthenic syndrome characterized by kinetic abnormalities of the AChR. In most cases, FCCMS is due to mutations that decrease activity of the AChR by slowing the rate of opening of the receptor channel, speeding the rate of closure of the channel, or decreasing the number of openings of the channel during ACh occupancy. The result is failure to achieve threshold depolarization of the endplate and consequent failure to fire an action potential. Belongs to the ligand-gated ion channel (TC 1.A.9) family. Acetylcholine receptor (TC 1.A.9.1) subfamily. Alpha- 1/CHRNA1 sub-subfamily. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Channel, cation; Membrane protein, multi-pass; Receptor, misc.; Membrane protein, integral; Channel, ligand-gated

Chromosomal Location of Human Ortholog: 2q31.1

Cellular Component: cell junction; cell surface; neuromuscular junction; nicotinic acetylcholine-gated receptor-channel complex; plasma membrane; postsynaptic membrane

Molecular Function: acetylcholine binding; acetylcholine receptor activity; ion channel activity; nicotinic acetylcholine-activated cation-selective channel activity

Biological Process: generation of action potential; muscle maintenance; musculoskeletal movement; neuromuscular junction development; neuromuscular process; neuromuscular synaptic transmission; regulation of membrane potential; response to nicotine; signal transduction; skeletal muscle contraction; skeletal muscle growth; synaptic transmission; synaptic transmission, cholinergic; transport

Disease: Multiple Pterygium Syndrome, Lethal Type; Myasthenic Syndrome, Congenital, Fast-channel; Myasthenic Syndrome, Congenital, Slow-channel